infliximab Archives - Buhlmann Diagnostics Corp

Tag: infliximab

The New Biosimilar of Infliximab SB2 Can be Quantified by IFX-Optimized Therapeutic Drug Monitoring Assays

BÜHLMANN Quantum Blue® Infliximab Citation: Magro, F., Rocha, C. et al. P229 The new biosimilar of infliximab SB2 can be quantified by IFX-optimized therapeutic drug monitoring assays.  Journal of Crohns and Colitis.  2018, Jan. DOI: 10.1093/ecco-jcc/jjx180.356. BÜHLMANN Quantum Blue® Infliximab is for Research Use Only in the US.  Not for use in diagnostic procedures in the US. Health Canada License:
Continue Reading

A Pilot Study Using Point of Care Testing for Infliximab and Faecal Calprotectin in IBD Patients

BÜHLMANN Quantum Blue® Infliximab Citation: Sophie Restellini, Talat Bessissow, Carolyne Lemieux, Che-Yung Chao, Gary Wild, Ernest Seidman, Alain Bitton, Peter L. Lakatos, Waqqas Afif.  P711 A pilot study using point of care testing for infliximab and faecal calprotectin in IBD patients with a secondary loss of response.  Journal of Crohn's and Colitis. 2018 Jan. DOI: 10.1093/ecco-jcc/jjx180.838. Highlight from this
Continue Reading

Exploration of Predictive Biomarkers of Early Infliximab Response in Acute Severe Colitis: A Prospective Pilot Study

BÜHLMANN fCAL® ELISA Citation:  Beswick, L. et al. Exploration of predictive biomarkers of early infliximab response in acute severe colitis: A prospective pilot study.  Journal of Crohn's and Colitis. 2017 Nov 7. DOI: 10.1093/ecco-jcc/jjx146.  PMID:  29121178 . Highlight from this Publication “In ASUC, post-first dose IFX, early assessment of serum/faecal IFX, calprotectin and partial Mayo scores can accurate predict future
Continue Reading